GALAPAGOS N.V. | 67.25 / -2.64% |
Date/Time | 04/23 / 18:30 |
Chg. / Chg.(%) | -1.82 / -2.64% |
Bid | 67.24 / 25 |
Ask | 67.42 / 25 |
Open | 68.71 |
Previous Close | 69.07 |
High | 69.45 |
Low | 67.01 |
Volume [EUR] | 0.00 |
Volume [Units] | 0 |
Price fixings | 14 |
ISIN | BE0003818359 |
Security | GXE |
Exchange | Düsseldorf |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
London Inter.. | 68.98 | ![]() |
474,074 |
Euronext - A.. | 67.34 | ![]() |
385,714 |
Cboe Europe .. | 67.38 | ![]() |
100,658 |
Turquoise | 67.37 | ![]() |
42,181 |
TradeGate | 67.32 | ![]() |
1,472 |
Xetra | 67.36 | ![]() |
300 |
Cboe Europe .. | 68.65 | ![]() |
145 |
gettex | 67.740 | ![]() |
34 |
Nasdaq Other.. | 81.2598 | ![]() |
20 |
Düsseldorf | 67.25 | ![]() |
0 |
München | 68.90 | ![]() |
0 |
Berlin | 67.35 | ![]() |
0 |
Frankfurt | 67.1200 | ![]() |
0 |
Vienna Globa.. | 67.32 | ![]() |
0 |
Lang & Schwa.. | 67.19 | ![]() |
|
Stuttgart | 68.730 | ![]() |
|
Cboe Europe .. | 69.07 | 416 |
News
- Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies
06:01 - GlobeNewswire - OXURION NV to Present at Wet AMD and DME Drug Development Summit
04/13/2021 / 07:30 - GlobeNewswire - Extension of lock-up period in Gilead-Galapagos collaboration agreement
04/08/2021 / 22:01 - GlobeNewswire - Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
04/07/2021 / 17:45 - GlobeNewswire - Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group
04/06/2021 / 07:30 - GlobeNewswire